Bristol-Myers Squibb Company (BMY)

Feb 21, 2025, 3:36 PM EST - 1 day ago

Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success

Feb 20, 2025, 12:49 AM EST - 2 days ago

BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing

Feb 19, 2025, 8:09 AM EST - 3 days ago

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields

OGN PFE

Feb 19, 2025, 6:59 AM EST - 3 days ago

Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer

Feb 16, 2025, 7:53 AM EST - 6 days ago

Buy 5 'Safer' Dividend Dogs Of 23 February Barron's Better Bets Than T-Bills

AG BBY EQR ETR FRT KEY KIM

Feb 16, 2025, 6:59 AM EST - 6 days ago

New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis

Feb 13, 2025, 4:16 PM EST - 9 days ago

Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial

Feb 10, 2025, 10:41 AM EST - 12 days ago

What's Going On With Bristol Myers Squibb Stock On Monday?

Feb 10, 2025, 8:15 AM EST - 12 days ago

Bristol-Myers Squibb: Cobenfy's Strong Launch And 2025 Growth Outlook

Feb 10, 2025, 6:59 AM EST - 12 days ago

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

Feb 7, 2025, 1:00 PM EST - 15 days ago

Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down

Feb 6, 2025, 1:44 PM EST - 16 days ago

Trade Tracker: Josh Brown sells Bristol Myers after buying it on Monday

Feb 6, 2025, 1:41 PM EST - 16 days ago

Bristol-Myers Squibb Company (BMY) Q4 2024 Earnings Conference Call Transcript

Feb 6, 2025, 12:08 PM EST - 16 days ago

Dow Dips 150 Points; Bristol Myers Squibb Issues Weak Outlook

Feb 6, 2025, 9:50 AM EST - 16 days ago

Cramer's Mad Dash: Bristol Myers

Feb 6, 2025, 9:08 AM EST - 16 days ago

Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts

Feb 6, 2025, 7:01 AM EST - 16 days ago

Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance

Feb 6, 2025, 6:59 AM EST - 16 days ago

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024

Feb 4, 2025, 1:28 PM EST - 18 days ago

Trade Tracker: Josh Brown buys Bristol-Myers

Feb 4, 2025, 7:14 AM EST - 18 days ago

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

CVS PINC

Jan 31, 2025, 3:31 PM EST - 22 days ago

Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts

GILD MRK

Jan 31, 2025, 6:59 AM EST - 22 days ago

Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

Jan 31, 2025, 6:50 AM EST - 22 days ago

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma

Jan 29, 2025, 9:00 AM EST - 24 days ago

10 Undervalued Dividend Growth Stocks: January 2025

HRL HSY KMB NVS PEP PFE SPY

Jan 25, 2025, 10:02 AM EST - 4 weeks ago

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy

Jan 23, 2025, 6:31 PM EST - 4 weeks ago

Final Trade: ET, DELL, KRE, BMY

DELL ET KRE

Jan 23, 2025, 4:17 AM EST - 4 weeks ago

How To Invest $100,000 In The Ten Cheapest Dow Dividend 100 Stocks

ABBV AMGN BLK CSCO CVX EOG HD

Jan 19, 2025, 4:54 PM EST - 4 weeks ago

Top 4 Immunology Stocks Poised For Growth In 2025

ABBV TEVA SNY

Jan 15, 2025, 10:56 AM EST - 5 weeks ago

Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug

Jan 13, 2025, 7:58 PM EST - 5 weeks ago

Feedback on schizophrenia treatment has been great, says Bristol Myers Squibb CEO

Jan 13, 2025, 2:00 PM EST - 5 weeks ago

Bristol-Myers Squibb Company (BMY) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Jan 13, 2025, 7:00 AM EST - 5 weeks ago

ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors

Jan 9, 2025, 6:28 AM EST - 6 weeks ago

Buy 6 'Safer' Dividend Dogs Of 23 January Barron's Better Bets Than T-Bills

BBY CAG EQR FRT KEY KIM LYB

Jan 8, 2025, 11:13 AM EST - 6 weeks ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO IOVA LLY MDGL MRK PFE

Jan 3, 2025, 12:06 PM EST - 7 weeks ago

Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz

ABT HOLX LLY NVO UNH XBI XLV

Jan 3, 2025, 6:59 AM EST - 7 weeks ago

Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference

Jan 2, 2025, 6:17 PM EST - 7 weeks ago

Final Trade: XLE, PANW, XHB, BMY

XLE PANW XHB

Dec 31, 2024, 7:05 AM EST - 7 weeks ago

Drugmakers to raise US prices on over 250 medicines starting Jan. 1

PFE SNY

Dec 30, 2024, 12:30 PM EST - 7 weeks ago

Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval

Dec 27, 2024, 5:37 PM EST - 2 months ago

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2

Dec 27, 2024, 11:35 AM EST - 2 months ago

US FDA approves injectable form of Bristol Myers' Opdivo

Dec 23, 2024, 6:59 AM EST - 2 months ago

Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis

Dec 23, 2024, 6:45 AM EST - 2 months ago

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer

Dec 20, 2024, 2:00 PM EST - 2 months ago

Bristol-Myers Squibb: Rich Dividends & Double-Digits Upside Potential - Bright 2026 Prospects

Dec 20, 2024, 8:00 AM EST - 2 months ago

Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued

Dec 19, 2024, 8:30 AM EST - 2 months ago

Imbed Biosciences Appoints Bristol Myers Squibb Veteran Terry Bromley as Chief Executive Officer

Dec 19, 2024, 6:59 AM EST - 2 months ago

Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025

Dec 19, 2024, 1:48 AM EST - 2 months ago

BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program

Dec 18, 2024, 11:40 PM EST - 2 months ago

Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare

Dec 18, 2024, 9:00 AM EST - 2 months ago

Bristol-Myers: Still An Opportunity Yielding Over 4%